Drugs / COA566
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01256658 | Nov 2010 → Jul 2012 | malaria | Novartis | Completed | Missed primary |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-24 | Novartis Pharmaceuticals | Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants novartis.com ↗ |
| 2015-07-16 | Novartis Pharmaceuticals | Novartis malaria treatment Coartem® 80/480mg receives WHO prequalification, enabling greater access for patients novartis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COA566 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01256658 ↗ |
| Known as | Coartem | “A Community Setting Study of Malaria After Systematic Treatment of Symptomatic Carriers of P. Falciparum With COA566 (Coartem®)” NCT01256658 ↗ |